Evaluating Future Directions for Biomarker-Guided Care in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Jason Mouabbi and Dr. Seth Wander discuss evolving questions surrounding the implementation of biomarker-guided treatment strategies in HR-positive, HER2-negative advanced breast cancer. The experts review practical considerations for molecular testing approaches, including the potential use of focused biomarker panels versus broader genomic profiling to identify resistance mechanisms such as ESR1 mutations. Dr. Wander discusses the balance between efficient clinical testing and the value of comprehensive molecular data for advancing research and identifying future therapeutic targets. The conversation also explores remaining questions regarding earlier intervention based on emerging resistance markers, including the need to continue evaluating long-term outcomes, sequencing approaches, and optimal clinical integration. Dr. Mouabbi and Dr. Wander emphasize that continued research will be important to refine personalized treatment strategies and improve care for patients with HR-positive, HER2-negative advanced breast cancer.